Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT ODT versus EDROPHONIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT ODT versus EDROPHONIUM CHLORIDE.
ARICEPT ODT vs EDROPHONIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
None Documented
None Documented
Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations.
Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor
Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor